Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cibus, Inc.CLXT · Entity 6658 | Director of Business Developme | June 20, 2018 | June 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cibus, Inc.
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,990 |
Last balance in matching sequence
After 2018-06-20 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-06-20 · Exercise / conversion · Acquired 6,500 · Balance 31,490 F1: Includes 24,990 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 4,410 will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Row 2 · 2018-06-20 · Sale · Disposed 6,500 · Balance 24,990 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2017. F1: Includes 24,990 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 4,410 will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2026-04-07 | Direct | 112,500 |
Reported balance
After 2018-06-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-06-20 · Exercise / conversion · Disposed 6,500 · Balance 112,500 F3: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 24,990 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 4,410 will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2017.
F3: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2018 Filed Jun 22, 2018 19:49 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001127602-18-021748 · form4.xml · derivative · entry 3 Arbadji Michel · CIK 0001712089 · Director of Business Developme 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 6,500 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 19:49 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 6,500 | $22.00 | $143,000.00 |
DisclosureSEC source: 0001127602-18-021748 · form4.xml · nonDerivative · entry 2 Arbadji Michel · CIK 0001712089 · Director of Business Developme 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,990 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2017. F1 · balance_after: Includes 24,990 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 4,410 will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 19:49 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 6,500 | $3.59 | $23,320.70 |
DisclosureSEC source: 0001127602-18-021748 · form4.xml · nonDerivative · entry 1 Arbadji Michel · CIK 0001712089 · Director of Business Developme 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 24,990 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 4,410 will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 19:43 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,410 | $18.75 | $82,705.58 |
DisclosureSEC source: 0001127602-18-021141 · form4.xml · nonDerivative · entry 1 Arbadji Michel · CIK 0001712089 · Director of Business Developme 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,990 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2017. F2 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $18.65-$18.97, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: Includes 24,990 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 4,410 will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:02 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right-to-Buy) · Derivative | 3,500 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001615594-18-000017 · primary_doc.xml · derivative · entry 3 Arbadji Michel · CIK 0001712089 · Director of Business Developme 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,000 Underlying: Common Stock · 3,500 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:02 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 3,500 | $18.63 | $65,219.70 |
DisclosureSEC source: 0001615594-18-000017 · primary_doc.xml · nonDerivative · entry 2 Arbadji Michel · CIK 0001712089 · Director of Business Developme 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,400 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05-18.82, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:02 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 3,500 | $3.59 | $12,557.30 |
DisclosureSEC source: 0001615594-18-000017 · primary_doc.xml · nonDerivative · entry 1 Arbadji Michel · CIK 0001712089 · Director of Business Developme 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.